-
Benzyl Quinolone Carboxylic Acid (BQCA) Workflow
2026-08-16
Benzyl Quinolone Carboxylic Acid (BQCA) enables selective interrogation of M1 acetylcholine receptor signaling without relying solely on orthosteric agonist exposure. This practical guide connects concentration–response assays, BRET-based pathway profiling, and neuronal validation for cognitive function modulation and Alzheimer’s disease research.
-
OMV-Displayed mRNA Antigens for Personalized Tumor Vaccines
2026-08-15
The reference study developed engineered bacterial outer membrane vesicles (OMV-LL) that rapidly capture sequence-tagged mRNA antigens and promote dendritic-cell delivery, endosomal escape, and cross-presentation. In mouse tumor models, the platform inhibited melanoma, produced complete regression in a subset of colon tumors, and generated durable antitumor memory, while also offering a distinct strategy for personalized vaccine assembly.
-
TECPR1-Mediated Lysosomal Repair Under Energy Stress
2026-08-14
A 2026 Cell Research study identifies TECPR1 as a lysosomal repair factor that senses PI4P-enriched damaged membranes and cooperates with KIF1A to generate membrane tubules. The work connects lysosomal membrane remodeling with survival during glucose deprivation and liver protection in a metabolic dysfunction-associated fatty liver disease model.
-
Capsaicin as a KDM1A/LSD1 Inhibitor
2026-08-14
The reference study identifies Capsaicin, also called (E)-Capsaicin, as a direct, reversible, FAD-competitive inhibitor of lysine-specific demethylase 1A (KDM1A/LSD1). Its cellular data connect KDM1A inhibition with reduced gastric cancer cell migration and invasion through reversal of epithelial–mesenchymal transition, while also defining important limitations for translational interpretation.
-
SIS3: Selective Smad3 Inhibitor for Research
2026-08-13
SIS3 is a selective Smad3 inhibitor that suppresses Smad3 phosphorylation and Smad3–Smad4 signaling without affecting Smad2 phosphorylation, according to product information. Peer-reviewed osteoarthritis research links SIS3 treatment with reduced ADAMTS-5 expression and increased miRNA-140 in rat cartilage models.
-
Regulated Cell Death Mechanisms in Heart Disease
2026-08-13
Konstantinidis, Whelan, and Kitsis integrate evidence showing that apoptosis and necrosis are distinct but interconnected outcomes of shared death-signaling networks in myocardial infarction and heart failure. The review’s main practical contribution is a framework for interpreting regulated necrosis, mitochondrial and endoplasmic-reticulum signaling, ATP loss, and inflammatory injury when designing cardiovascular cell-death experiments.
-
Protease Inhibitor Cocktail: MS-Safe Workflow
2026-08-12
Learn how to use a 50X, AEBSF-free Protease Inhibitor Cocktail to preserve proteins during cell and tissue extraction without compromising mass spectrometry workflows. The guide connects cold-chain handling, pH-aware sample design, optional EDTA supplementation, and troubleshooting to practical proteomics and structural assays.
-
DFCP1 Controls Starvation-Driven ATGL Lipolysis
2026-08-12
The reference study identifies DFCP1/ZFYVE1 as a nutrient-sensitive regulator of lipid droplet catabolism that recruits ATGL to droplets during starvation. Its findings connect DFCP1-dependent spatial control of ATGL residence time with reduced lipolysis, providing a mechanistic framework for studying lipid mobilization and associated protein complexes.
-
Lipo3K Transfection Reagent for APOL1 Assays
2026-08-11
Discover how Lipo3K Transfection Reagent can support controlled APOL1 variant, splice-isoform, and APOL3 interaction studies. This guide translates recent APOL1 mechanistic findings into practical assay design, transfection controls, and interpretation strategies.
-
Protease Inhibitor Cocktail for Lipid Droplet Assays
2026-08-11
Protect DFCP1–ATGL complexes and other labile proteins during starvation, lipid droplet, cell lysate, and tissue extract workflows. This EDTA-containing, water-soluble protease inhibitor mixture adds broad-spectrum protection while requiring deliberate compatibility checks for IMAC, kinase, and metal-dependent assays.
-
SCH772984 HCl: ERK Control of TERT
2026-08-10
Explore how SCH772984 HCl, a potent ERK1/2 inhibitor, can connect MAPK pathway activity with TERT transcription and chromatin state. This article translates recent stem-cell findings into practical assay decisions for cancer signaling and resistance research.
-
KPT330 and Cas9 Precision: mRNA Export Control
2026-08-09
The reference study identifies selective inhibitors of nuclear export, particularly KPT330, as indirect regulators of Cas9, base-editor, and prime-editor activity. By restricting nuclear export of Cas9 mRNA rather than binding the Cas9 protein directly, this strategy provides a route to reduce excessive editing activity and improve specificity in human cells.
-
BAY-826: A Causal Map for Retinal Signaling
2026-08-08
BAY-826 is a potent small molecule inhibitor for dissecting Ang–Tie-2 signaling, Müller cell communication, and retinal neuron survival. This article focuses on causal assay design, pathway attribution, and practical controls rather than repeating a conventional product overview.
-
Prostaglandin E2: From Metabolomics to Assay Design
2026-08-07
Prostaglandin E2 links receptor-level perturbation with tissue-resolved metabolomics and systems pharmacology. This guide shows how PGE2 can improve assay decisions without overstating what complex cardiovascular disease models prove.
-
Redefining CRISPR Precision with Advanced Cas9 mRNA Engineer
2026-08-07
This thought-leadership article presents a mechanistic and strategic perspective on leveraging advanced mRNA engineering for CRISPR-Cas9 genome editing. We integrate biological rationale, recent breakthroughs in mRNA export modulation, and practical workflow guidance, focusing on the unique properties of EZ Cap™ Cas9 mRNA (m1Ψ). By connecting recent peer-reviewed findings with translational research needs, we deliver actionable insights for maximizing editing precision, minimizing off-target effects, and accelerating clinical translation.